NO325595B1 - E-2-[4-(4-klor-1,2-difenyl-but-1-enyl)fenoksy]etanol og farmasoytiske sammensetninger og anvendelser derav - Google Patents
E-2-[4-(4-klor-1,2-difenyl-but-1-enyl)fenoksy]etanol og farmasoytiske sammensetninger og anvendelser derav Download PDFInfo
- Publication number
- NO325595B1 NO325595B1 NO20003987A NO20003987A NO325595B1 NO 325595 B1 NO325595 B1 NO 325595B1 NO 20003987 A NO20003987 A NO 20003987A NO 20003987 A NO20003987 A NO 20003987A NO 325595 B1 NO325595 B1 NO 325595B1
- Authority
- NO
- Norway
- Prior art keywords
- diphenyl
- chloro
- ethanol
- enyl
- phenoxy
- Prior art date
Links
- LUMKNAVTFCDUIE-WCWDXBQESA-N 2-[4-[(e)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(/CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-WCWDXBQESA-N 0.000 title claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 33
- 150000002148 esters Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000002657 hormone replacement therapy Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 229960005026 toremifene Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000001833 anti-estrogenic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001076 estrogenic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- -1 acetic acid Chemical class 0.000 description 4
- 238000009806 oophorectomy Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- OYXIKBMCUBZEPS-NVQSTNCTSA-N (e)-3,4-diphenyl-4-[4-(2-phenylmethoxyethoxy)phenyl]but-3-en-1-ol Chemical compound C=1C=CC=CC=1C(/CCO)=C(C=1C=CC(OCCOCC=2C=CC=CC=2)=CC=1)\C1=CC=CC=C1 OYXIKBMCUBZEPS-NVQSTNCTSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 229960004622 raloxifene Drugs 0.000 description 3
- XARXSXPYKRGUFO-NVQSTNCTSA-N 1-[(e)-4-chloro-1,2-diphenylbut-1-enyl]-4-(2-phenylmethoxyethoxy)benzene Chemical compound C=1C=CC=CC=1C(/CCCl)=C(C=1C=CC(OCCOCC=2C=CC=CC=2)=CC=1)\C1=CC=CC=C1 XARXSXPYKRGUFO-NVQSTNCTSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013223 sprague-dawley female rat Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JRAPAWFDOQVLLC-QURGRASLSA-N 4-[(e)-4-hydroxy-1,2-diphenylbut-1-enyl]phenol Chemical compound C=1C=CC=CC=1C(/CCO)=C(C=1C=CC(O)=CC=1)\C1=CC=CC=C1 JRAPAWFDOQVLLC-QURGRASLSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008687 biosynthesis inhibition Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9803521.5A GB9803521D0 (en) | 1998-02-19 | 1998-02-19 | New compounds and pharmaceutical compositions thereof |
| PCT/FI1999/000137 WO1999042427A1 (en) | 1998-02-19 | 1999-02-19 | E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol and pharmaceutical compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20003987D0 NO20003987D0 (no) | 2000-08-07 |
| NO20003987L NO20003987L (no) | 2000-08-07 |
| NO325595B1 true NO325595B1 (no) | 2008-06-23 |
Family
ID=10827263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20003987A NO325595B1 (no) | 1998-02-19 | 2000-08-07 | E-2-[4-(4-klor-1,2-difenyl-but-1-enyl)fenoksy]etanol og farmasoytiske sammensetninger og anvendelser derav |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6395785B1 (es) |
| EP (1) | EP1056701B1 (es) |
| JP (1) | JP2002503713A (es) |
| KR (1) | KR100755918B1 (es) |
| CN (1) | CN1161314C (es) |
| AR (1) | AR014961A1 (es) |
| AT (1) | ATE252531T1 (es) |
| AU (1) | AU755798B2 (es) |
| BG (1) | BG64471B1 (es) |
| BR (1) | BR9907688A (es) |
| CA (1) | CA2321122C (es) |
| CZ (1) | CZ294315B6 (es) |
| DE (1) | DE69912247T2 (es) |
| DK (1) | DK1056701T3 (es) |
| EA (1) | EA002919B1 (es) |
| EE (1) | EE04233B1 (es) |
| ES (1) | ES2211038T3 (es) |
| GB (1) | GB9803521D0 (es) |
| GE (1) | GEP20022794B (es) |
| HR (1) | HRP20000545A2 (es) |
| HU (1) | HUP0101354A3 (es) |
| ID (1) | ID26857A (es) |
| IL (1) | IL137214A (es) |
| NO (1) | NO325595B1 (es) |
| NZ (1) | NZ505637A (es) |
| PL (1) | PL193315B1 (es) |
| PT (1) | PT1056701E (es) |
| RS (1) | RS49660B (es) |
| SK (1) | SK285940B6 (es) |
| TR (1) | TR200002037T2 (es) |
| UA (1) | UA57132C2 (es) |
| WO (1) | WO1999042427A1 (es) |
| ZA (1) | ZA991232B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| SI1235776T1 (sl) * | 1999-11-16 | 2006-06-30 | Hormos Medical Corp | Trifenilalkenski derivati in njihova uporaba kot selektivni estrogenski receptorski modulatorji |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| CN101448490A (zh) | 2006-05-22 | 2009-06-03 | 霍尔莫斯医疗有限公司 | 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂 |
| EP2121553B1 (en) | 2007-02-14 | 2012-06-27 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
| US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
| CN102770402B (zh) | 2010-01-19 | 2016-01-20 | 坎布雷卡尔斯库加公司 | 制造二苯甲酮衍生物的新方法 |
| JP6174156B2 (ja) | 2012-10-19 | 2017-08-02 | フェルミオン オサケ ユキチュア | オスペミフェンの製造方法 |
| US20150321983A1 (en) * | 2012-10-19 | 2015-11-12 | Fermion Oy | A process for the preparation of ospemifene |
| CN104030896A (zh) * | 2013-03-07 | 2014-09-10 | 天津药物研究院 | 一种简易去除欧司哌米芬特异杂质的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| GB9604577D0 (en) * | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
-
1998
- 1998-02-19 GB GBGB9803521.5A patent/GB9803521D0/en not_active Ceased
-
1999
- 1999-02-16 ZA ZA9901232A patent/ZA991232B/xx unknown
- 1999-02-16 AR ARP990100642A patent/AR014961A1/es active IP Right Grant
- 1999-02-19 TR TR2000/02037T patent/TR200002037T2/xx unknown
- 1999-02-19 PT PT99904899T patent/PT1056701E/pt unknown
- 1999-02-19 WO PCT/FI1999/000137 patent/WO1999042427A1/en active IP Right Grant
- 1999-02-19 AT AT99904899T patent/ATE252531T1/de not_active IP Right Cessation
- 1999-02-19 DE DE69912247T patent/DE69912247T2/de not_active Expired - Fee Related
- 1999-02-19 GE GEAP19995553A patent/GEP20022794B/en unknown
- 1999-02-19 US US09/601,612 patent/US6395785B1/en not_active Expired - Fee Related
- 1999-02-19 CA CA002321122A patent/CA2321122C/en not_active Expired - Fee Related
- 1999-02-19 RS YUP-510/00A patent/RS49660B/sr unknown
- 1999-02-19 AU AU25244/99A patent/AU755798B2/en not_active Ceased
- 1999-02-19 KR KR1020007008982A patent/KR100755918B1/ko not_active IP Right Cessation
- 1999-02-19 ES ES99904899T patent/ES2211038T3/es not_active Expired - Lifetime
- 1999-02-19 BR BR9907688-8A patent/BR9907688A/pt not_active Application Discontinuation
- 1999-02-19 SK SK1205-2000A patent/SK285940B6/sk unknown
- 1999-02-19 HU HU0101354A patent/HUP0101354A3/hu unknown
- 1999-02-19 JP JP2000532381A patent/JP2002503713A/ja active Pending
- 1999-02-19 NZ NZ505637A patent/NZ505637A/xx unknown
- 1999-02-19 CN CNB998030139A patent/CN1161314C/zh not_active Expired - Fee Related
- 1999-02-19 IL IL13721499A patent/IL137214A/xx unknown
- 1999-02-19 EA EA200000851A patent/EA002919B1/ru not_active IP Right Cessation
- 1999-02-19 PL PL342445A patent/PL193315B1/pl unknown
- 1999-02-19 ID IDW20001841A patent/ID26857A/id unknown
- 1999-02-19 CZ CZ20002927A patent/CZ294315B6/cs not_active IP Right Cessation
- 1999-02-19 DK DK99904899T patent/DK1056701T3/da active
- 1999-02-19 EE EEP200000473A patent/EE04233B1/xx not_active IP Right Cessation
- 1999-02-19 EP EP99904899A patent/EP1056701B1/en not_active Expired - Lifetime
- 1999-02-19 UA UA2000095331A patent/UA57132C2/uk unknown
-
2000
- 2000-08-07 NO NO20003987A patent/NO325595B1/no unknown
- 2000-08-18 HR HR20000545A patent/HRP20000545A2/xx not_active Application Discontinuation
- 2000-08-28 BG BG104713A patent/BG64471B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW399036B (en) | Naphthyl compounds, intermediates, pharmaceutical, compositions, and preparation process thereof | |
| TW434238B (en) | Anti-estrogen compounds and pharmaceutically acceptable salts thereof, and pharmaceutical composition for treating estrogen-sensitive diseases | |
| EP1169336B1 (en) | Ent-steroids as selectively active estrogens | |
| JP4113583B2 (ja) | 血清コレステロール低下薬 | |
| NO325595B1 (no) | E-2-[4-(4-klor-1,2-difenyl-but-1-enyl)fenoksy]etanol og farmasoytiske sammensetninger og anvendelser derav | |
| JPH07215871A (ja) | 血清コレステロールを減少させるための方法 | |
| US20060270845A1 (en) | 16-Hydroxyestratrienes as selectively active estrogens | |
| US20090029957A1 (en) | 8-beta-substituted estratrienes as selectively active estrogens | |
| WO1998028324A9 (fr) | Steroides substitues en position 11, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant | |
| WO1998028324A1 (fr) | Steroides substitues en position 11, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant | |
| MXPA00008134A (es) | E-2-[4-(4-cloro-1,2-difenil-but-1-enil)fenoxi]etanol y composiciones farmaceuticas del mismo | |
| Sorbera et al. | CP-336156 | |
| AU2004201405A1 (en) | Ent-Steroids as selectively active estrogens |